Sutro Biopharma logo

Sutro Biopharma Share Price Today

(NASDAQ: STRO)

Sutro Biopharma share price is $1.36 & ₹118.41 as on 6 Mar 2025, 2.30 'hrs' IST

$1.36

-0.06

(-4.23%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Sutro Biopharma share price in Dollar and Rupees. Guide to invest in Sutro Biopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Sutro Biopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Sutro Biopharma share price movements

  • Today's Low: $1.34
    Today's High: $1.44

    Day's Volatility :7.29%

  • 52 Weeks Low: $1.34
    52 Weeks High: $6.13

    52 Weeks Volatility :78.22%

Sutro Biopharma (STRO) Returns

PeriodSutro Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
-51.08%
3.7%
0.0%
6 Months
-68.3%
-2.8%
0.0%
1 Year
-71.06%
2.5%
0.0%
3 Years
-82.87%
12.9%
-11.6%

Sutro Biopharma (STRO) Key Statistics

in dollars & INR

Previous Close
$1.42
Open
$1.4
Today's High
$1.44
Today's Low
$1.335
Market Capitalization
$117.1M
Today's Volume
$990.4K
52 Week High
$6.13
52 Week Low
$1.335
Revenue TTM
$161.0M
EBITDA
$-123.0M
Earnings Per Share (EPS)
$-1.54
Profit Margin
-77.01%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-110.89%

How to invest in Sutro Biopharma Stock (STRO) from India?

It is very easy for Indian residents to invest directly in Sutro Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Sutro Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Sutro Biopharma or STRO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Sutro Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Sutro Biopharma shares which would translate to 0.640 fractional shares of Sutro Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Sutro Biopharma, in just a few clicks!

Returns in Sutro Biopharma (STRO) for Indian investors in Rupees

The Sutro Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Sutro Biopharma investment value today

Current value as on today

₹34,001

Returns

₹65,999

(-66%)

Returns from Sutro Biopharma Stock

₹71,064 (-71.06%)

Dollar Returns

₹5,065 (+5.06%)

Indian investors sentiment towards Sutro Biopharma (STRO)

-10%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Sutro Biopharma Stock from India on INDmoney has decreased by -10% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Sutro Biopharma

  • BlackRock Inc

    9.21%

  • Suvretta Capital Management, LLC

    9.05%

  • Vanguard Group Inc

    5.10%

  • Kynam Capital Management, LP

    4.42%

  • Vestal Point Capital LP

    3.12%

  • Citadel Advisors Llc

    2.98%

Analyst Recommendation on Sutro Biopharma

Buy

    87%Buy

    12%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Sutro Biopharma(by analysts ranked 0 to 5 stars)

Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
13
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Sutro Biopharma Stock (STRO)

What analysts predicted

Upside of 745.59%

Target:

$11.50

Current:

$1.36

Insights on Sutro Biopharma Stock (Ticker Symbol: STRO)

  • Price Movement

    In the last 7 days, STRO stock has moved down by -12.3%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 25.70M → 8.52M (in $), with an average decrease of 66.9% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -48.01M → -48.78M (in $), with an average decrease of 1.6% per quarter
  • STRO vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 137.6%
  • STRO vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 135.0%
  • Price to Sales

    ForSTRO every $1 of sales, investors are willing to pay $0.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

STRO Sutro Biopharma Financials in INR & Dollars

FY18Y/Y Change
Revenue
$38.4M
↓ 25.75%
Net Income
$-35.3M
↑ 79.38%
Net Profit Margin
-91.93%
↓ 53.88%
FY19Y/Y Change
Revenue
$42.7M
↑ 11.24%
Net Income
$-55.7M
↑ 57.84%
Net Profit Margin
-130.44%
↓ 38.51%
FY20Y/Y Change
Revenue
$42.7M
↓ 0.03%
Net Income
$-36.2M
↓ 35.05%
Net Profit Margin
-84.75%
↑ 45.69%
FY21Y/Y Change
Revenue
$61.9M
↑ 44.84%
Net Income
$-108.7M
↑ 200.17%
Net Profit Margin
-175.62%
↓ 90.87%
FY22Y/Y Change
Revenue
$67.8M
↑ 9.52%
Net Income
$-119.2M
↑ 9.69%
Net Profit Margin
-175.89%
↓ 0.27%
FY23Y/Y Change
Revenue
$153.7M
↑ 126.84%
Net Income
$-106.8M
↓ 10.41%
Net Profit Margin
-69.47%
↑ 106.42%
Q2 FY23Q/Q Change
Revenue
$10.4M
↓ 17.85%
Net Income
$-38.5M
↓ 23.03%
Net Profit Margin
-370.0%
↑ 24.9%
Q3 FY23Q/Q Change
Revenue
$16.9M
↑ 62.54%
Net Income
$-49.3M
↑ 27.93%
Net Profit Margin
-291.21%
↑ 78.79%
Q4 FY23Q/Q Change
Revenue
$113.7M
↑ 571.95%
Net Income
$31.1M
↓ 163.03%
Net Profit Margin
27.32%
↑ 318.53%
Q1 FY24Q/Q Change
Revenue
$13.0M
↓ 88.56%
Net Income
$-58.2M
↓ 287.39%
Net Profit Margin
-447.52%
↓ 474.84%
Q2 FY24Q/Q Change
Revenue
$25.7M
↑ 97.62%
Net Income
$-48.0M
↓ 17.51%
Net Profit Margin
-186.8%
↑ 260.72%
Q3 FY24Q/Q Change
Revenue
$8.5M
↓ 66.86%
Net Income
$-48.8M
↑ 1.6%
Net Profit Margin
-572.62%
↓ 385.82%
FY18Y/Y Change
Profit
$38.4M
↓ 25.75%
FY19Y/Y Change
Profit
$-22.9M
↓ 159.54%
FY20Y/Y Change
Profit
$-34.2M
↑ 49.67%
FY21Y/Y Change
Profit
$52.1M
↓ 252.19%
FY22Y/Y Change
Profit
$59.5M
↑ 14.16%
FY23Y/Y Change
Profit
$146.9M
↑ 146.98%
Q2 FY23Q/Q Change
Profit
$8.0M
↓ 23.05%
Q3 FY23Q/Q Change
Profit
$15.2M
↑ 89.41%
Q4 FY23Q/Q Change
Profit
$112.0M
↑ 637.5%
Q1 FY24Q/Q Change
Profit
$11.2M
↓ 89.96%
Q2 FY24Q/Q Change
Profit
$-36.3M
↓ 422.88%
Q3 FY24Q/Q Change
Profit
$8.5M
↓ 123.46%
FY18Y/Y Change
Operating Cash Flow
$12.7M
↓ 134.21%
Investing Cash Flow
$-80.2M
↓ 345.97%
Financing Cash Flow
$170.8M
↑ 1066.64%
FY19Y/Y Change
Operating Cash Flow
$-65.0M
↓ 612.68%
Investing Cash Flow
$-51.1M
↓ 36.24%
Financing Cash Flow
$-4.2M
↓ 102.45%
FY20Y/Y Change
Operating Cash Flow
$-67.8M
↑ 4.27%
Investing Cash Flow
$604.0K
↓ 101.18%
Financing Cash Flow
$269.2M
↓ 6535.16%
FY21Y/Y Change
Operating Cash Flow
$-81.7M
↑ 20.47%
Investing Cash Flow
$-97.3M
↓ 16211.75%
Financing Cash Flow
$3.3M
↓ 98.79%
FY22Y/Y Change
Operating Cash Flow
$3.5M
↓ 104.35%
Investing Cash Flow
$-35.0M
↓ 64.01%
Financing Cash Flow
$48.3M
↑ 1383.81%
Q2 FY23Q/Q Change
Operating Cash Flow
$-31.2M
↓ 48.85%
Investing Cash Flow
$66.2M
↓ 1.92%
Financing Cash Flow
$137.7M
↑ 1471.83%

Sutro Biopharma Technicals Summary

Sell

Neutral

Buy

Sutro Biopharma is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Sutro Biopharma (STRO) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sutro Biopharma Inc logo
-31.66%
-68.3%
-71.06%
-82.87%
-84.24%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sutro Biopharma Inc logo
NA
NA
NA
-3.07
-1.11
-0.18
NA
1.35
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sutro Biopharma Inc logo
Buy
$117.1M
-84.24%
NA
-77.01%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Sutro Biopharma

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Organization
Sutro Biopharma
Employees
306
CEO
Mr. William J. Newell J.D.
Industry
Health Technology

Management People of Sutro Biopharma

NameTitle
Mr. William J. Newell J.D.
CEO & Director
Dr. Hans-Peter Gerber Ph.D.
Chief Scientific Officer
Dr. Anne Elizabeth Borgman-Hagey M.D.
Chief Medical Officer
Ms. Jane Chung R.Ph.
President & COO
Dr. James R. Swartz DSc, Ph.D., Sc.D.
Founder
Mr. Edward C. Albini M.B.A
CFO & Secretary
Dr. Venkatesh Srinivasan Ph.d.
Chief Technical Operations Officer
Mr. David Pauling J.D., M.A.
General Counsel
Ms. Linda A. Fitzpatrick
Chief People & Communications Officer
Dr. Barbara Leyman Ph.D.
Chief Business Development Officer

Important FAQs about investing in STRO Stock from India :

What is Sutro Biopharma share price today?

Sutro Biopharma share price today stands at $1.36, Open: $1.40 ; Previous Close: $1.42 ; High: $1.44 ; Low: $1.34 ; 52 Week High: $6.13 ; 52 Week Low: $1.34.

The stock opens at $1.40, after a previous close of $1.42. The stock reached a daily high of $1.44 and a low of $1.34, with a 52-week high of $6.13 and a 52-week low of $1.34.

Can Indians buy Sutro Biopharma shares?

Yes, Indians can invest in the Sutro Biopharma (STRO) from India.

With INDmoney, you can buy Sutro Biopharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Sutro Biopharma at zero transaction cost.

How can I buy Sutro Biopharma shares from India?

It is very easy to buy Sutro Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Sutro Biopharma (STRO) be purchased?

Yes, you can buy fractional shares of Sutro Biopharma with INDmoney app.

What are the documents required to start investing in Sutro Biopharma stocks?

To start investing in Sutro Biopharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Sutro Biopharma Stock (STRO)?

Today’s highest price of Sutro Biopharma (STRO) is $1.44.

Today’s lowest price of Sutro Biopharma (STRO) is $1.34.

What is today's market capitalisation of Sutro Biopharma?

Today's market capitalisation of Sutro Biopharma STRO is 117.1M

What is the 52 Week High and Low Range of Sutro Biopharma Stock (STRO)?

  • 52 Week High

    $6.13

  • 52 Week Low

    $1.34

What are the historical returns of Sutro Biopharma (STRO)?

  • 1 Month Returns

    -31.66%

  • 3 Months Returns

    -68.3%

  • 1 Year Returns

    -71.06%

  • 5 Years Returns

    -84.24%

Who is the Chief Executive Officer (CEO) of Sutro Biopharma ?

Mr. William J. Newell J.D. is the current Chief Executive Officer (CEO) of Sutro Biopharma.